Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MESH1-mediated coenzyme A degradation drives ferroptosis sensitivity and muscle pathology
Chao-Chieh Lin, Joshua Rose, Alexander A. Mestre, Chien-Kung Cornelia Ding, Ssu-Yu Chen, Sze Mun Choy, Kah Yong Goh, Weiyi Jiang, Wen Xing Lee, Qizhou Jiang, Yanting Chen, Tianai Sun, Jianli Wu, Yueqi Chen, Yunju Oh, Pyeonghwa Jeong, Jiyong Hong, Kenon Chua, Michael C. Fitzgerald, Guo-Fang Zhang, Hong-Wen Tang, Pei Zhou, Jen-Tsan Chi
Chao-Chieh Lin, Joshua Rose, Alexander A. Mestre, Chien-Kung Cornelia Ding, Ssu-Yu Chen, Sze Mun Choy, Kah Yong Goh, Weiyi Jiang, Wen Xing Lee, Qizhou Jiang, Yanting Chen, Tianai Sun, Jianli Wu, Yueqi Chen, Yunju Oh, Pyeonghwa Jeong, Jiyong Hong, Kenon Chua, Michael C. Fitzgerald, Guo-Fang Zhang, Hong-Wen Tang, Pei Zhou, Jen-Tsan Chi
View: Text | PDF
Research Article Cell biology Muscle biology

MESH1-mediated coenzyme A degradation drives ferroptosis sensitivity and muscle pathology

  • Text
  • PDF
Abstract

CoA facilitates fatty acid synthesis, energy production, gene regulation, and antioxidant function. While CoA biosynthesis is well characterized, the mechanisms governing CoA degradation remain poorly understood. Here, we identify the Metazoan Homolog of SpoT, MESH1, as a CoA phosphatase that dephosphorylates CoA at the 3′ position of the ribose ring to form dephospho-CoA. Recent studies have shown that CoA, similar to glutathione, is a cysteine-derived metabolite that protects cells against ferroptosis. Ferroptosis induced by blocking cystine import depletes CoA biosynthesis, while CoA restoration rescues cells from ferroptosis. We found that MESH1 knockdown preserved CoA levels by preventing its degradation, contributing to ferroptosis protection, indicating the bifunctional role of MESH1 in regulating CoA and previously reported NADPH. Mechanistically, MESH1 knockdown elevates CoA levels, maintaining a functional mitochondrial thioredoxin system, thereby preventing mitochondrial lipid peroxidation. In Drosophila, we found that dMesh1 overexpression leads to ferroptosis-mediated muscle atrophy, which can be rescued by increasing CoA and NADPH levels. Taken together, these findings establish MESH1 as a key phosphatase that governs ferroptosis sensitivity by coordinating CoA and NADPH homeostasis, unveiling a link between CoA degradation, mitochondrial integrity, and muscle health.

Authors

Chao-Chieh Lin, Joshua Rose, Alexander A. Mestre, Chien-Kung Cornelia Ding, Ssu-Yu Chen, Sze Mun Choy, Kah Yong Goh, Weiyi Jiang, Wen Xing Lee, Qizhou Jiang, Yanting Chen, Tianai Sun, Jianli Wu, Yueqi Chen, Yunju Oh, Pyeonghwa Jeong, Jiyong Hong, Kenon Chua, Michael C. Fitzgerald, Guo-Fang Zhang, Hong-Wen Tang, Pei Zhou, Jen-Tsan Chi

×

Figure 2

The CoA level preserved by MESH1 knockdown protects against ferroptosis.

Options: View larger image (or click on image) Download as PowerPoint
The CoA level preserved by MESH1 knockdown protects against ferroptosis....
(A) The dp-CoA/CoA ratio in HEK293T cells overexpressing empty vector, WT-MESH1, and the catalytically null mutant (MESH1-E65A) as determined by mass spectrometry. (B) MESH1 knockdown preserved CoA levels degraded upon erastin treatment, as quantified by CoA assay. HT-1080 cells were transfected with control or 2 independent MESH1 siRNAs for 2 days and treated with erastin for 18 hours to quantify CoA level. (C) CoA biosynthesis is required for the protective effect of MESH1 knockdown upon erastin treatment. HT-1080 cells were transfected individually or in combination with MESH1 and COASY siRNAs for 2 days, subjected to 24 hours of erastin treatment, and quantified by Cell-Titer Glo assay. (D and E) COASY knockdown abolished the protective effect of MESH1 knockdown on erastin-induced (2.5 μM, 20 hours) membrane rupture in HT-1080 cells, while CoA supplement (100 μM) rescued membrane rupture in all conditions. The results were observed by CellTox Green under a fluorescence microscope (D) and quantified by a plate reader (E). Scale bars: 200 μm. (F) PANKi (5 μM, chemical inhibitor of PANK) abolished the protective effects of MESH1 knockdown upon erastin treatment in HT-1080 cells. (G) PANKi (5 μM) abolished the protective effects of MESH1 knockdown in HT-1080 cells by ferroptosis, and this resensitization was rescued by ferroptosis inhibitors. CoA (100 μM); ferrostatin-1 (fer-1, 10 μM); liproxstatin-1 (lip-1, 2 μM); deferoxamine (DFO, 80 μM); NAC (500 μM). (H and I) Double knockdown of NADK (NADPH synthesis) and COASY (CoA synthesis) fully abolished the protective effects of MESH1 knockdown, as quantified by Cell-Titer Glo assay (H) and CellTox Green (I). (A and G) One-way ANOVA, Tukey’s multiple comparisons, n = 3 independent biological replicates. (B, C, E, F, H, and I) Two-way ANOVA, Šidák’s multiple comparisons, n = 3 independent biological replicates; data are shown as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts